Long-term results with lanreotide in patients with recurrent gastrointestinal angiodysplasias bleeding or obscure gastrointestinal bleeding. Benefits in efficacy and procedures consumption

References

• Gerson LB, Fidler JL, Cave DR, et al. ACG Clinical Guideline: diagnosis and management of small bowel bleeding. Am J Gastroenterol. 2015;110:1265–1287.
   PubMed Web of Science ®Google Scholar
• Raju GS, Gerson L, Das A, et al. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology. 2007;133:1694–1696.
   PubMedGoogle Scholar
• Regula J, Wronska E, Pachlewski J. Vascular lesions of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2008;22:313–328.
   PubMed Web of Science ®Google Scholar
• Grooteman KV, Matheeuwsen M, van Geenen EJM, et al. Decreased health-related quality of life in angiodysplasia patients: a cross-sectional cohort. PLoS One. 2017;12:e0177522.
   PubMed Web of Science ®Google Scholar
• Romagnuolo J, Brock AS, Ranney N. Is endoscopic therapy effective for angioectasia in obscure gastrointestinal bleeding?: a systematic review of the literature. J Clin Gastroenterol. 2015;49:823–830.
   PubMed Web of Science ®Google Scholar
• Jarbandhan S, van der Veer WM, Mulder CJ. Double-balloon endoscopy in the diagnosis and treatment of hemorrhage from retrovalvular angiodysplasias. J Gastrointest Liver Dis. 2008;17:333–334.
   PubMed Web of Science ®Google Scholar
• Gady JS, Reynolds H, Blum A. Selective arterial embolization for control of lower gastrointestinal bleeding: recommendations for a clinical management pathway. Curr Surg. 2003;60:344. 47
   PubMedGoogle Scholar
• Jackson CS, Gerson LB. Management of Gastrointestinal Angiodysplastic Lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:474–483.
   PubMed Web of Science ®Google Scholar
• Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141:1629–1637.
   PubMed Web of Science ®Google Scholar
• Garrido A, Sayago M, Lopez J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig. 2012;104:69–71.
   PubMed Web of Science ®Google Scholar
• Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol. 2006;20:171–178.
   PubMed Web of Science ®Google Scholar
• Nardone G, Rocco A, Balzano T, et al. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther. 1999;13:1429–1436.
   PubMed Web of Science ®Google Scholar
• Nardone G, Compare D, Martino A, et al. Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: a position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis. 2018;50:542–548.
   PubMedGoogle Scholar
• Brown C, Subramanian V, Wilcox CM, et al. Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Dig Dis Sci. 2010;55:2129–2134.
   PubMed Web of Science ®Google Scholar
• Chetcuti Zammit S, Sanders DS, Sidhu R. Refractory anaemia secondary to small bowel angioectasias - comparison between endotherapy alone versus combination with somatostatin analogues. J Gastrointestin Liver Dis. 2017;26:369–374.
   PubMed Web of Science ®Google Scholar
• Junquera F, Saperas E, Videla S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol. 2007;102:254–260.
   PubMed Web of Science ®Google Scholar
• Bon C, Aparicio T, Vincent M, et al. Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Aliment Pharmacol Ther. 2012;36:587–593.
   PubMed Web of Science ®Google Scholar
• Nardone G, Compare D, Scarpignato C, et al. Long acting release-octreotide as "rescue" therapy to control angiodysplasia bleeding: a retrospective study of 98 cases. Dig Liver Dis. 2014;46:688–694.
   PubMedGoogle Scholar
• Klímová K, Padilla-Suárez C, Giménez-Manzorro Á, et al. Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study. Rev Esp Enferm Dig. 2015;107:79–88.
   PubMed Web of Science ®Google Scholar
• Holleran G, Hall B, Breslin N, et al. Long-acting somatostatin analogues provide significant beneficial effect in patients with refractory small bowel angiodysplasia: results from a proof of concept open label mono-centre trial. United European Gastroenterol J. 2016;4:70–76.
   PubMed Web of Science ®Google Scholar
• Molina Infante J, Pérez Gallardo B, Hernández Alonso M, et al. Octreotide long acting release for severe obscure gastrointestinal haemorrhage in elderly patients with serious comorbidities. Med Clin (Barc). 2009;133:667–670.
   PubMed Web of Science ®Google Scholar
• Scaglione G, Pietrini L, Russo F, et al. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Aliment Pharmacol Ther. 2007;26:935–942.
   PubMed Web of Science ®Google Scholar
• Chetcuti Zammit S, Sanders DS, Sidhu R. Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre. Scand J Gastroenterol. 2017;52:962–968.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770–776.
   PubMed Web of Science ®Google Scholar
• Grooteman KV, van Geenen EJM, Drenth JPH. Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial. BMJ Open. 2016;6:e011442.
   PubMed Web of Science ®Google Scholar